SEC Form 4 · accession 0001012975-19-000197

Sienna Biopharmaceuticals, Inc. · SNNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Kristina Burow

Director

Period of report

Feb 22, 2019

Accepted (ET)

Feb 26, 2019 · 9:03 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001656328

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 22, 2019	P	150,000	$2.50	A	2,900,575	I	See footnote
Common Stock^F2	Feb 22, 2019	P	150,000	$2.50	A	1,032,493	I	See footnote
Common Stock^F3	Feb 22, 2019	P	1,865,800	$2.50	A	1,865,800	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The shares are directly held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII and ARCH VIII LLC may therefore be deemed to beneficially own the securities held by ARCH Fund VIII. The Reporting Person has an interest in ARCH Partners VIII and ARCH VIII LLC, but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F2The shares are directly held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH VIII LLC. ARCH VIII LLC may therefore be deemed to beneficially own the securities held by ARCH Fund Overage. The Reporting Person has an interest in ARCH VIII LLC, but does not have voting or investment control over the shares held by ARCH Fund Overage. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F3The shares are directly held of record by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). The sole general Partner of ARCH X Overage is ARCH Venture Partners X Overage, L.P. ("AVP X Over GP"). The sole general partner of AVP X Over GP is ARCH Venture Partners X, LLC ("AVP X LLC"). AVP X Over LP and AVP X LLC may therefore be deemed to beneficially own the securities held by ARCH X Overage. AVP X Over GP and AVP X LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The Reporting Person is a managing director of AVP X LLC and may be deemed to beneficially own the shares held by ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.